Latest Current Report
Filed: 2026-03-17
Key Insights
- CNBX Pharmaceuticals obtained a $45,000 non-convertible promissory note from 3i L.P. to be used for immediate working capital purposes and expenditures.
- The note has a simple interest rate of 5% per annum and is due on July 1, 2026, providing short-term financing for the company.
- As an emerging growth company, CNBX Pharmaceuticals may have flexibility in complying with new or revised financial accounting standards.